The activation of platelets is stimulated or inhibited by numerous hormones, drugs, eicosanoids, and other vasoactive substances. Agonists such as thrombin, thromboxane, vasopressin, platelet-activating factor, and ADP elevate the cytosolic free Ca 2ϩ and stimulate the activity of myosin light chain kinase and PKC 1 resulting in platelet adhesion, aggregation, and degranulation (1, 2) . Most platelet agonists activate phospholipase C and elevate [Ca 2ϩ ] i by an InsP 3 -dependent release of Ca 2ϩ from the intracellular stores, as well as stimulation of the entry of extracellular Ca 2ϩ (2) (3) (4) (5) . The agonist-releasable stores appear to be of two different types, distinguishable by the sensitivity of their Ca 2ϩ -ATPases to low thapsigargin (Tg) concentrations or to 2,5-di-tert-butylhydroquinone (or high Tg concentrations), respectively (6 -8) .
The modes of Ca 2ϩ entry are controversial. It is generally agreed that a substantial influx is activated by a signal generated by the depletion of the intracellular stores (capacitative Ca 2ϩ influx) (9) also in the absence of agonist, e.g. by treatment with the endomembrane Ca 2ϩ -ATPase inhibitor Tg (10, 11) ; such a signal could be a small molecule released together with the Ca 2ϩ ions from the stores (12, 13) , but also other possibilities cannot be excluded (14 -16) . Receptor-mediated influx systems are also operative. ADP induces a very fast Ca 2ϩ entry which precedes the release from the intracellular stores and the subsequent second phase of Ca 2ϩ entry (4) . We recently found that the occupancy of the thrombin receptor activates a store-independent Ca 2ϩ influx (17) . Ca 2ϩ efflux from platelets is operated by a Ca 2ϩ -ATPase, whose activity is potentiated by the activation of PKC (18, 19) as well as by the depletion of the stores (19) .
The cyclic nucleotides cAMP and cGMP exert multiple inhibitory actions on platelet activation. cAMP was shown to decrease the binding of thrombin to its receptor on human platelets (20) . In the presence of cAMP, the activation of phospholipase C (and hence the production of InsP 3 and diacylglycerol) by the agonist is depressed, leading to the inhibition of the increment of [Ca 2ϩ ] i and of PKC-dependent phosphorylations (21) . The action of cAMP is also on events distal to the activation of phospholipase C since platelet aggregation and secretion induced by the Ca 2ϩ ionophore ionomycin or by phorbol esters are also inhibited by the cyclic nucleotide (22) (23) (24) . cAMP also increases the incorporation of diacylglycerol into phosphatidylinositol (25) .
Similar inhibitory actions were reported for cGMP, which interferes with the agonist-induced activation of phospholipase C (26 -30) and also affects events distal to the increase of [Ca 2ϩ ] i (31, 32) . Furthermore, cGMP potentiates the action of cAMP elevating agents, by inhibiting the cAMP phosphodiesterase (33) .
The cyclic nucleotides also interfere with the Ca 2ϩ influx. We recently reported that cAMP and cGMP inhibit the thrombinactivated Ca 2ϩ influx in platelets, without interfering with the Ca 2ϩ influx secondary to the depletion of the intracellular stores (17) . An inhibition by cAMP and cGMP has been reported recently on Ca 2ϩ influx activated by thromboxane (34) . On the contrary, the ADP-activated Ca 2ϩ influx has been reported to be insensitive to cAMP (3) .
The action of cAMP and cGMP on Ca 2ϩ movements to and from the intracellular deposits is controversial and has received considerable attention. The activity of PKA was reported to be facilitatory, or even necessary, for Ca 2ϩ release by InsP 3 from isolated platelet membrane vesicles (35) . This conclusion was refuted (36) . The catalytic subunit of PKA was reported to stimulate Ca 2ϩ uptake by platelet membrane vesicles (35, 37, 38) . This effect was correlated with the phosphorylation of a protein tentatively identified with phospholamban, the known promoter of Ca 2ϩ transport in cardiac muscle membranes, but that identity was disputed (39) . On the other hand, dibutyryl cAMP, and various prostaglandins and forskolin, are known to stimulate adenylate cyclase and reverse the Ca 2ϩ mobilization produced by platelet agonists (40 -42) . Furthermore, the addition of cAMP to saponin-permeabilized platelets was reported to decrease the amount of Ca 2ϩ released by the InsP 3 -sensitive stores (43) . Similar results were obtained with the catalytic subunit of PKA (4).
Finally, it was also proposed that cAMP and cGMP potentiate the action of the plasma membrane Ca 2ϩ -ATPase (45) . The present study was performed to settle some controversy concerning the action of cAMP and cGMP on Ca 2ϩ movements between cytosol and the stores. It is shown that both cyclic nucleotides are without effect on the Ca 2ϩ pumps (including the plasma membrane Ca 2ϩ pump) and that their action is to prevent the Ca Platelet Preparation-Platelet-rich plasma and washed platelets were prepared and treated with aspirin as previously reported (22) from fresh blood drawn from healthy volunteers and mixed with acid citratedextrose anticoagulant supplemented with hirudin (50 milliunits/ml) apyrase (80 milliunits/ml) and PGI 2 (0.2 g/ml).
Determination of Cytosolic Free Ca 2ϩ Concentration-The intracellular Ca 2ϩ concentration was determined with Indo 1/AM essentially according to Pollock and Rink (47) . The Ca 2ϩ fluorescent probe (2 M) was added to aspirin-treated platelet-rich plasma, and loading was performed for 30 min at 37°C. After centrifugation, the pellet was resuspended in Tyrode's buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 20 mM Na-Hepes, 10 mM glucose, pH 7.4) in the presence of 0.1 mM sulfinpyrazone (48), 40 milliunits/ml apyrase, and 5 milliunits/ml hirudin. The platelets were used at the concentration of 1 ϫ 10 8 cells/ml. All experiments were performed in the presence 0.5 mM EGTA. Unless otherwise stated, fluorescence was measured at 37°C in a thermostated, magnetically stirred cuvette, in a Shimadzu RL-5000 spectrofluorimeter with excitation and emission wavelengths set at 340 nm and 400 nm.
Determination of InsP 3 -The amount of InsP 3 was determined on 0.5-ml aliquots of platelet suspensions (5-6 ϫ 10 8 cells/ml) precipitated with 5% (v:v) ice-cold perchloric acid. After 20 min in ice, the deproteinized samples were centrifuged at 8000 ϫ g for 5 min and neutralized with KHCO 3 . The samples were used for the InsP 3 determination with the Amersham radioimmunoassay kit and following its specifications.
Platelet Permeabilization and Ca 2ϩ Release by Exogenous InsP 3 -For the detection of Ca
2ϩ release induced by exogenous InsP 3 , platelets were suspended in Tyrode's buffer (not supplemented with hirudin and apyrase) at 2 ϫ 10 9 /ml. Immediately before use, they were diluted five times with a KCl buffer (100 mM KCl, 100 mM sucrose, 1.4 mM MgCl 2 , 20 mM K-Hepes, pH 7.4) and supplemented with (final concentrations): NaN 3 (1 mM), oligomycin (0.6 g/ml), phosphocreatine (7.5 mM), creatine kinase (30 g/ml), ATP (1 mM), KH 2 PO 4 (1 mM), and Fluo 3 (4 M). Free Ca 2ϩ was decreased to approximately 300 nM with EGTA (based on a K d for Ca 2ϩ of Fluo 3 of 316 nM). Permeabilization was induced with saponin (20 -30 g/ml, the correct concentration had to be adjusted with each preparation). After uptake, Ca 2ϩ was released by pulses of InsP 3 as described in the figures. Calibration were performed by back-titration of the Ca 2ϩ traces with pulses of 2 M EGTA. EDTA was removed from the PKA preparation by an ultrafiltration procedure (Minicent 10 Bio-Rad, 10 Kilodalton cutoff, filters). Fluorescence was measured at excitation and emission wavelengths set at 488 and 526 nm.
Immunodetection of the InsP 3 Receptor-Incubation of the platelet suspension (4 ϫ 10 8 cells/ml) was terminated by the addition of 1/5 volume of modified Laemmli's buffer (1.46 M Tris, 11.5% (w/v) SDS, 7.7% mercaptoethanol, 23% glycerol, and 30 mM dithiothreitol) at pH 6.8 followed by overnight room temperature denaturation. One-dimensional SDS electrophoresis was performed on two-step (5 and 11%) polyacrylamide minigels. The gels were colored with Coomassie Blue for the identification of the protein pattern or subjected to electrophoretic transfer (4 h at 450 mA) onto nitrocellulose membranes (Hoefer Scientific Instruments TM-NC4-roll) for subsequent probing with an antiInsP 3 receptor (mouse monoclonal) antibody. The blots were preincubated for 30 min with 5% (w/v) BSA in 0.1 M Tris, 0.15 M NaCl saline buffer, pH 7.5, containing 0.1% Tween (TBST buffer) to block residual protein binding sites. Immunodetection of InsP 3 receptor was achieved by using the monoclonal anti-InsP 3 receptor antibody for 1 h at 37°C diluted 1:100 in TBST buffer. The primary antibody was then removed, and the blots washed three times in TBST containing 1% BSA. To detect the primary antibody, the blots were incubated with biotinylated antimouse antibody (diluted 1:3000) for 30 min, washed 3 times in TBST, and then incubated with streptavidin-alkaline phosphatase complex (1:3000), washed again 3 times in TBST, and then exposed to the Bio-Rad chemiluminescent reagents for 30 min (49) . Blots were then revealed by exposition for a time ranging from 3 to 10 min to photographic film.
P i Loading and Analysis of Protein Phosphorylation-

32
P i loading was performed by incubating platelets at a concentration of 2 ϫ 10 9 cells with 300 Ci/ml 32 P i for 60 min at room temperature. After diluting 10 times with Tyrode's buffer containing 0.2 g/ml PGI 2 and 3 mg/ml BSA, platelets were centrifuged, and the pellet was resuspended in Tyrode's buffer for the subsequent stimulation at a concentration of 4 ϫ 10 8 cells/ml. Platelets were incubated as specified in the legends to Figs. 7 and 8. The incubations were terminated with the Laemmli buffer, and electrophoresis was performed as described above. The gels were colored and counted for at least a 10-h exposition to the ␤ emission sensitive scanner-Instant Imager (Packard Instruments). Occasionally, counting was performed on the transblots. Analysis of the p260 and p47 phosphorylation for data reported in Fig. 8 was performed on a single band integration of the counts/min patterns obtained by the Instant Imager.
RESULTS
PGI 2 and SNP Potentiate Ca
2ϩ Reuptake into the Stores-As described by us (17, 19) and others (50, 51) , the addition of the agonist thrombin to aspirin-treated platelets resuspended in an EGTA-supplemented medium elicits a large increase of [Ca 2ϩ ] i followed by a relatively rapid decrease close to the baseline, which is completed in 3-5 min. The decrease of [Ca 2ϩ ] i is attributable to a relatively large extent to a net reuptake into the intracellular stores, since the subsequent addition of the endomembrane Ca 2ϩ -ATPase inhibitor Tg, together with a small amount of ionomycin to facilitate the release from the stores (17) , releases into the cytosol a significant proportion of the disappeared Ca 2ϩ (Fig. 1) . The decrease of [Ca 2ϩ ] i is strongly stimulated if PGI 2 or SNP (which generate cAMP and cGMP, respectively) are added soon after the peak of the thrombin-induced increase of [Ca 2ϩ ] i (Fig. 1) ) is significantly higher than in the control. Similar results are obtained also with the membrane-permeable dibutyryl-cAMP and 8-Br-cGMP, although they stimulate the decrease of [Ca 2ϩ ] i somewhat less powerfully than PGI 2 and SNP (results not reported). These experiments show that increasing cAMP or cGMP potentiates Ca 2ϩ reuptake into the stores, apparently without major effects on Ca 2ϩ efflux from platelets. The pattern in Fig. 1 is unchanged by the specific PKC inhibitor GF 109 203X (3 M) which decreases only somewhat the decay rate of [Ca 2ϩ ] i after thrombin; the stimulated decay by PGI 2 and SNP are on the contrary totally abolished by staurosporine (1-2 M) which also inhibits PKA and PKG (results not reported).
PGI 2 and SNP Are without Effect on the Activity of Platelet Ca
2ϩ Pumps-The potentiation of Ca 2ϩ reuptake into the stores promoted by the cyclic nucleotides could depend in principle on the increased activity of the store-and plasma membrane-associated Ca 2ϩ -ATPases or on the inhibition of Ca 2ϩ release from the deposits. In order to distinguish between these possibilities, we introduced a new method which utilizes the Ca 2ϩ ionophore ionomycin to mobilize Ca 2ϩ without the intervention of agonists or inhibitors, followed by BSA to remove the ionophore. As described in Fig. 2 , the addition of ionomycin to platelets suspended in EGTA-supplemented media induces a large increase of [Ca 2ϩ ] i , released from the agonist-sensitive stores as well as from the secretory granules (19) . At the ionomycin concentration used (400 nM), the agonist-sensitive deposits are largely depleted (as shown by the small increase of [Ca 2ϩ ] i upon addition of Tg at the top of the ionomycin-induced deflection, Fig. 2B ). The subsequent addition of BSA, which binds the ionophore, allows the study of the decay of [Ca 2ϩ ] i , operated by the Ca 2ϩ pumps, in the absence of perturbing agents. As shown in Fig. 2A , the decay of [Ca 2ϩ ] i is very rapid upon addition of BSA (note that this experiment was performed at 20°C to decrease the activity of the pumps). Two processes contribute to the depletion of [Ca 2ϩ ] i , namely pumping into the stores and pumping into the extracellular space. The use of Tg to inhibit the endomembrane Ca 2ϩ -ATPases allows quantitation of the contribution of each system to the overall decay rate. The decay of [Ca 2ϩ ] i is strongly depressed by the inclusion of Tg prior to BSA (Fig. 2, compare B and A) showing that pumping into the stores prevails over pumping out of the platelets.
The addition of PGI 2 or SNP prior to ionomycin has no effect on the ionophore-induced increase of [Ca 2ϩ ] i and importantly also has no effect on the rate of decrease of [Ca 2ϩ ] i upon addition of BSA, both in the absence ( Fig. 2A) and presence (Fig. 2B) of Tg. Accordingly, the refilling of the stores after BSA (in the experiment without Tg, Fig. 2A) , as measured by the increase of [Ca 2ϩ ] i following the addition of Tg, is unmodified by PGI 2 and SNP. This is more clearly shown (with an expanded time scale) in Fig. 3 , where, after ionomycin, BSA was supplemented both at submaximal and at maximal concentrations. At the lower BSA concentrations, some ionomycin is left unbound and activates variable degrees of Ca 2ϩ cycling. In these conditions, the combined action of the Ca 2ϩ pumps and the ionomycin-induced leaks leads to the establishment of in- ] i upon removal of ionomycin with BSA, which is unaffected by increasing platelet cAMP and cGMP, is on the contrary strongly decreased if thrombin is supplemented together with BSA (Fig. 2C ). This may be expected since the production of InsP 3 induced by thrombin activates a InsP 3 -dependent (and BSA-insensitive) Ca 2ϩ efflux from the deposits, which counteracts the action of the endomembrane Ca 2ϩ pumps, thus decreasing the overall decay rate of [Ca 2ϩ ] i . Accordingly, the amount of Ca 2ϩ reaccumulated in the stores (shown by the increase of [Ca 2ϩ ] i upon addition of Tg) is significantly less in the presence of thrombin (Fig. 2, compare C and A) . This experiment shows that PGI 2 and SNP oppose the Ca 2ϩ efflux from the deposits induced by the thrombin-produced InsP 3 .
Since the cyclic nucleotides appear not to modify the activity of the Ca 2ϩ pumps, but rather to oppose the effect of InsP 3 , we measured the thrombin-induced production of InsP 3 and the effect of supplementing PGI 2 or SNP, after thrombin, on the platelet InsP 3 content. As shown in Fig. 4 , InsP 3 increases sharply soon after the addition of thrombin, to progressively decrease to a lower steady state value. The addition of PGI 2 or SNP 10 s after thrombin, at a time when InsP 3 has reached its maximum, is without effect on the InsP 3 levels which remain undistinguishable from those observed with thrombin alone. This finding shows that the cAMP and cGMP potentiation of Ca 2ϩ uptake into the stores (Fig. 1 ) is mediated by a decrease of Ca 2ϩ efflux rather than by an increase in influx (Fig. 2) , and this takes place with no variation of InsP 3 concentration.
To monitor directly the effect of cAMP and cGMP on the Ca 2ϩ release promoted by exogenous InsP 3 , we also performed experiments in saponin-permeabilized platelets. The amount of 
Intracellular Ca 2ϩ Release Is Regulated by InsP 3 Receptor Phosphorylation
saponin required for the permeabilization was variable and had to be adjusted in each platelet preparation. A large Ca 2ϩ uptake into the endoplasmic reticulum is promoted by ATP upon permeabilization. Once the loading of the stores is completed, Ca 2ϩ is released stepwise by graded pulses of InsP 3 . The Ca 2ϩ released by low concentrations of InsP 3 is strongly decreased by cAMP. The inhibition is frequently slightly potentiated further by the inclusion of PKA (the effect, however, was not appreciated in all preparations). This may be expected since saponin permeabilizes the plasma membrane to large molecules, thus allowing the loss into the medium of many proteins and cofactors. The effect of cAMP disappears at high InsP 3 concentrations. A typical experiment is reported in Fig.   5 , and the cumulative results from several different platelet preparations are reported in Fig. 6 (the points are taken from experiments performed in the presence and absence of exogenous PKA). Similar experiments with cGMP gave essentially superimposable results.
PGI 2 and SNP Induce a Rapid Phosphorylation of the InsP 3 Receptor-The observation that increasing cAMP or cGMP counteracts the Ca 2ϩ -releasing action of InsP 3 is consistent with the idea that PGI 2 and SNP modify the InsP 3 receptor in such a way that it becomes less sensitive to the action of InsP 3 . Therefore, we attempted to separate and identify the InsP 3 receptor protein and to search for its cAMP-and cGMP-dependent phosphorylation. As shown in Fig. 7A, a 
gel electrophoresis separations of human platelets. Two bands of protein phosphorylation are rapidly induced by PGI 2 (or SNP) at the same levels (the higher molecular mass band is always more evident). This is shown in Fig. 7C , which reports the time course of the PGI 2 -induced phosphorylation of the InsP 3 receptor in conditions identical with Fig. 1 (GF 109 203X was also included to prevent thrombin from slowly phosphorylating the receptor). The progress of the receptor phosphorylation (higher molecular mass band) induced by PGI 2 , SNP, or thrombin (in the presence and absence of GF 109 203X) is presented in Fig. 8 , which also reports for comparison the phosphorylation of the typical 47-kDa PKC substrate pleckstrin. The experiments presented in Fig. 8 show that the increment of the InsP 3 receptor phosphorylation by PGI 2 and SNP is rapid enough to be compatible with its involvement in the mechanism of the acceleration of Ca 2ϩ reuptake into the stores depicted in Fig. 1 . Noticeably, the PKC-dependent phosphorylation of the InsP 3 receptor induced by thrombin, and sensitive to GF 109 203X, is much slower than that promoted by PGI 2 and SNP. It is concluded that the cyclic nucleotides do not modulate the Ca 2ϩ pumps and do not promote the disappearance of InsP 3 ; rather, they prevent InsP 3 from releasing Ca 2ϩ from the stores. Such an action of the cyclic nucleotides is unaffected by the specific PKC inhibitor GF 109 203X, but it is prevented by staurosporine, which inhibits both PKA and PKG.
The inhibition by the cyclic nucleotides of the Ca 2ϩ -releasing action of InsP 3 is observable directly in saponin-permeabilized platelets. The effect of cAMP and cGMP are best evident at low InsP 3 concentrations and disappear progressively with increasing InsP 3 . These results are similar to those reported for cAMP in cerebellum-derived microsomes (52) .
The inhibition by the cyclic nucleotides is accompanied by the phosphorylation, operated by both PGI 2 and SNP, of the InsP 3 receptor. The latter, as evidenced by its reactivity with a specific antibody, appears as two distinct bands in transblots from SDS-polyacrylamide gel electrophoresis separations of human platelets. Both bands are phosphorylated by PGI 2 and SNP, although the phosphorylation is more evident on the heavier band. The presence of two bands may indicate the occurrence in platelets of two different isoforms of the receptor, as already described in several organs (53, 54) . Alternatively, it may depend on variable degrees of glycosylation (55) or it was the result of a partial proteolysis at the NH 2 -terminal region of the receptor.
Both PKA (54, 56 -58) and PKG (59) are known to phosphorylate (at the same site) the InsP 3 receptor, which is also a substrate for PKC. In our experiments, a phosphorylation by thrombin, sensitive to the specific PKC inhibitor GF 109 203X is also observed; its onset is, however, remarkably slower than that promoted by PGI 2 and SNP (see also Ref. 54 ). The latter is fast enough to be compatible with its intervention in the inhibition of the receptor function. The slower PKC-dependent phosphorylation of the InsP 3 receptor may also be involved in the control of its sensitivity to InsP 3 . Indeed, we observed that staurosporine decreases Ca 2ϩ reuptake into the stores after its release by thrombin (19 and see also Ref. 60) , and a decrease of Ca 2ϩ reuptake was observed also in this study with the more specific PKC inhibitor GF 109 203X.
Different and frequently contrasting effects of the cAMP-dependent phosphorylation of the InsP 3 receptor are reported in the recent literature. After the initial observation by Supattapone et al. (52) that PKA inhibits the InsP 3 -induced Ca 2ϩ release in a rat cerebellar microsomal fraction preloaded with Ca 2ϩ , a cAMP-dependent phosphorylation was reported to potentiate the Ca 2ϩ -releasing effect of InsP 3 in vesicles reconstituted with a homotetrameric type I InsP 3 receptor (61) . In platelet membranes, data consistent with those of Supattapone et al. (52) were reported in Ref. 44 , but the effect of cAMP was not appreciated in isolated membranes (36) . This variability of data may relate to the presence of regulatory factors in microsomes that regulate the InsP 3 -dependent Ca 2ϩ release. Besides, PKA (PKG) may exert different effects on various subtypes of InsP 3 receptors that differ in their functional consequences. Indeed, in some cells, such as the hepatocytes, the Ca 2ϩ -releasing action of agonists is potentiated rather than inhibited by cAMP, which is therefore not expected to favor Ca 2ϩ reuptake in the stores (62, 63) . In this study, we used intact human platelets to study the mechanism by which PGI 2 and SNP so powerfully depress the [Ca 2ϩ ] i previously increased by thrombin. By dissecting and studying separately each of the intervening components, we could demonstrate that the action of cAMP and cGMP is to inhibit the Ca 2ϩ -releasing action of InsP 3 . The effect is accompanied by the rapid phosphorylation of the receptor. It seems inevitable to conclude that in the intact system the cyclic nucleotides promote a receptor phosphorylation that prevents InsP 3 from releasing the store-associated Ca 2ϩ . It may be concluded that both PGI 2 and SNP, besides depressing the agonist-induced activation of phospholipase C if they are presented to the platelets prior to the agonist, as extensively demonstrated in the literature, also oppose the effect of previously produced InsP 3 , by specifically inhibiting its Ca 2ϩ -releasing property.
